CHENGDU SHENGNUO BIOTEC CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.97 CNY | -0.33% |
|
-4.62% | -15.00% |
| 05-07 | Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection | MT |
| 04-22 | ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.00% | 370M | - | ||
| +19.64% | 43.3B | B- | ||
| +21.25% | 22.22B | B+ | ||
| +18.92% | 15.43B | - | ||
| +20.14% | 14.48B | B+ | ||
| +53.19% | 12.72B | B | ||
| -0.05% | 6.79B | - | - | |
| -11.11% | 6.71B | B+ | ||
| -8.87% | 5.73B | - | - | |
| +14.68% | 5.5B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688117 Stock
- Ratings ChengDu ShengNuo Biotec Co.,Ltd.